公开(公告)号：US20170233485A1

公开(公告)日：2017-08-17

申请号：US15504444

申请日：2015-08-18

Applicant: Biogen MA Inc.

Inventor： Linda C. Burkly ,  Janine Ferrant-Orgettas

IPC: C07K16/28

CPC classification number: C07K16/2878 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: Antibodies and antibody fragments that bind to human CD40 and inhibit interaction between CD40 and its ligand, CD40L are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit hyperactivation of B or T cells and treat or prevent disorders such as autoimmune diseases.

公开(公告)号：US20190233530A1

公开(公告)日：2019-08-01

申请号：US16379844

申请日：2019-04-10

Applicant: UCB BIOPHARMA SPRL ,  BIOGEN MA INC.

Inventor： Linda C. Burkly ,  Janine L. Ferrant-Orgettas ,  Ellen A. Garber ,  Yen-Ming Hsu ,  Lihe Su ,  Frederick R. Taylor ,  Ralph Adams ,  Derek Thomas Brown ,  Andrew George Popplewell ,  Martyn Kim Robinson ,  Anthony Shock ,  Kerry Louise Tyson

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/2875 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

公开(公告)号：US09775899B2

公开(公告)日：2017-10-03

申请号：US13718788

申请日：2012-12-18

Applicant: Biogen MA Inc.

Inventor： Linda C. Burkly ,  Kyungmin Hahm ,  Timothy Zheng ,  Steve Perrin ,  John Lincecum

IPC: A61K39/395 ,  G01N33/68 ,  A61K38/17

CPC classification number: A61K39/3955 ,  A61K38/1793 ,  G01N33/6896 ,  G01N2800/2814 ,  G01N2800/2835

Abstract: Methods of treating neuronal disorders, such as mechanical neuronal traumas and neurodegenerative disorders, with TWEAK or a TWEAK receptor blocking agents are presented.